8 Analysts Have This to Say About Arcutis Biotherapeutics
Portfolio Pulse from Benzinga Insights
Arcutis Biotherapeutics (NASDAQ:ARQT) has received 8 analyst ratings in the last quarter, with 6 being bullish and 2 somewhat bullish. The company has an average price target of $41.25, a decrease of 16.24% from the previous average price target of $49.25.

July 18, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Arcutis Biotherapeutics has received mostly bullish ratings from analysts, but the average price target has decreased, indicating a potential short-term negative impact on the stock.
The company has received mostly bullish ratings from analysts, which would typically indicate a positive outlook. However, the decrease in the average price target suggests that analysts are lowering their expectations for the stock, which could negatively impact its price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100